Avid Bioservices Inc (CDMO)

[sunstar]

Breast cancer, including triple negative breast cancer (TNBC) seems to now be ready for clinical I-O combinations between PPHM and AZN, and or through collaborations with Memorial Sloan Kettering, NCCN partners.

Immune Activation:

...immune activation for a combination of the preclinical bavituximab equivalent (ch1N11) and anti-PD-1 therapy in models of breast cancer including triple negative breast cancer (TNBC)."

What anti-PS offers to an I-O combination:

“...significant increase in overall survival and immunity to tumor re-challenge seen with the treatment combination as compared to anti-PD-1 therapy alone,”

How much?? anti-PS offers to an I-O combination:

“...the combination therapy significantly enhanced overall survival (p=0.0155) and was capable of mediating complete tumor regressions in a greater number of subjects compared to single agent treatments (60% vs. 20%).”

This is another example of the "Brekken Effect"...Bavi provides a 300% increased survival benefit to this I-O combination.



What's also very significant (and has been the sleeper here) is the forseeable end to metastases in cancer.

“...the combination treatment led to a prolonged anti-tumor immune response which protected the animals that achieved a complete tumor regression against a re-challenge with the same E0771 TNBC model tumor cells. This sustained anti-tumor response demonstrates the ability of the combination treatment to trigger immune system memory and support adaptive immune responses against reemerging disease in this TNBC model.”

IMO

sunstar